Sign Out
As with all alpha-1 blockers, some patients, and in particular those treated with antihypertensives may experience postural hypotension within a few hours following administration, possibly with symptoms (dizzy sensations, fatigue, sweating). If this occurs, patient should remain lying down until the symptoms have completely subsided. These effects are usually transient, occur at the beginning of treatment and do not generally prevent continued treatment. Pronounced drop in blood pressure has been reported in post-marketing surveillance in patients with pre-existing risk factors (such as underlying cardiac diseases and/or concomitant treatment with anti-hypertensive medication). Patients should be warned of the possible occurrence of these events. The risk of developing hypotension and related adverse reactions may be greater in elderly patients.
Treatment should be initiated gradually in patients with hypersensitivity to alpha-1 blockers.
APO-ALFUZOSIN 10 mg tablets should be administered carefully to patients being treated with antihypertensives.
Blood pressure should be monitored regularly, especially at the beginning of the treatment.
Caution is recommended, particularly in the elderly.
Use with caution in patients with acquired or congenital QT prolongation or who are taking medications that prolong the QT interval.
Intraoperative Floppy Iris Syndrome (IFIS, a small pupil syndrome variant) has been observed during cataract surgery in some patients previously or currently treated with tamsulosin. Isolated cases have also been reported with other alpha-1 blockers, therefore a possible class effect cannot be ruled out. Considering that IFIS can be the cause of additional technical difficulties during cataract operations, the surgeons must be informed of any history of current use of alpha-1 blockers before the eye surgery.
